Navigation Links
ADVENTRX Reports Third Quarter Financial Results
Date:11/8/2010

SAN DIEGO, Nov. 8, 2010 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today reported financial results for the three and nine months ended September 30, 2010.

"Our balance sheet remains strong due to our commitment to prudent cash management and reflected $29.3 million in cash at September 30," said Brian M. Culley, Chief Executive Officer of ADVENTRX.  "We recently submitted a New Drug Application to the FDA for our lead product candidate, Exelbine, as planned, and look forward to working with the FDA toward a potential approval for Exelbine next year," continued Mr. Culley.  

Third Quarter Financial ResultsADVENTRX's net loss applicable to common stock for the third quarter of 2010 was $1.8 million, or $0.13 per share, compared to net loss applicable to common stock of $2.7 million, or $0.57 per share, for the same period in 2009. Net loss applicable to common stock and net loss were the same for the three months ended September 30, 2010.  Net loss applicable to common stock for the three months ended September 30, 2009 included a non-cash, deemed dividend expense of $0.4 million related to the Company's July and August 2009 equity financings.  

Research and development (R&D) expenses for the third quarter of 2010 were $0.9 million, a decrease of $0.5 million, or 36%, compared to $1.4 million for the same period in 2009. The decrease was due primarily to a $1.0 million decrease in research-related manufacturing expenses for ANX-530, or Exelbine™, partially offset by a $0.3 million increase in fees for consulting services related to Exelbine and ANX-514 and a $0.2 million increase in toxicology study expenses related to Exelbine.

Selling, general and administrative (SG&A) expenses were $0.9 million for the third quarter of 2010 and for the same period in 2009.  

Year-to-Date
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Electrodes are devices that convert ... amplified to diagnose as well as treat several ... devices facilitate the detection of chemical reactions derived ... neurons of the patients. In addition, few electrodes ... current to perform minimally invasive surgical procedures. The ...
(Date:10/30/2014)... Oct. 29, 2014 CTI BioPharma Corp. (CTI) (NASDAQ ... months ended September 30, 2014. "During ... at the beginning of 2014 by securing a partner to ... expanding the market into countries where we do not have ... We believe this partnership will maximize the value of PIXUVRI ...
(Date:10/30/2014)... NEW YORK , Oct. 29, 2014 /PRNewswire/ ... strong growth through 2013 with the introduction of ... are well-covered in Vaccines: The World Market. The ... vaccines, covering specifically commercialized vaccines and developmental vaccines ... protects not only individuals, but also entire communities ...
Breaking Medicine Technology:Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 2Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 4CTI BioPharma Reports Third Quarter 2014 Financial Results 2CTI BioPharma Reports Third Quarter 2014 Financial Results 3CTI BioPharma Reports Third Quarter 2014 Financial Results 4CTI BioPharma Reports Third Quarter 2014 Financial Results 5CTI BioPharma Reports Third Quarter 2014 Financial Results 6CTI BioPharma Reports Third Quarter 2014 Financial Results 7CTI BioPharma Reports Third Quarter 2014 Financial Results 8CTI BioPharma Reports Third Quarter 2014 Financial Results 9CTI BioPharma Reports Third Quarter 2014 Financial Results 10CTI BioPharma Reports Third Quarter 2014 Financial Results 11CTI BioPharma Reports Third Quarter 2014 Financial Results 12Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 2Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 3
... , , MOUNTAIN VIEW, Calif., Dec. 16 ... patients in a Phase 2 clinical trial of CCX354, an ... CCR1 chemokine receptor for the treatment of rheumatoid arthritis (RA). ... of CCR1, a chemokine receptor that drives the recruitment of ...
... , , ... - Studies Conducted at INRA-Agroparistech Laboratory Under Pr. Daniel,Tome,s Supervision ... International Bone and Mineral Society "Bone", Reveal new Benefits for,Peptan(TM) ... to consumer concerns regarding long-term bone health,Rousselot has carried out, ...
Cached Medicine Technology:ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 2ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 3ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 4ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 5Published in "Bone" Journal, Scientific Researches Confirm Peptan(TM) Hydrolyzed Collagen Benefits on Bone Health 2
(Date:10/30/2014)... REV'D Provision Co. announced today that REV’D® ... unique service called, The Feed . The Feed ... athlete. The Feed has taken the nutritional knowledge used ... to pass that information on to the everyday athlete. ... on The Feed!” says REV’D® marketing manager Matt O’Connor. ...
(Date:10/30/2014)... The Woodlands, TX (PRWEB) October 30, 2014 ... hospital system, released today its 2014 third quarter ... hospitals across Texas boasted infection rates of only ... also reported patient satisfaction scores exceeding 98 percent. ... this past quarter, which included rising satisfaction scores,” ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- Scientists who ... the laboratory say their breakthrough could provide a new ... of stomach diseases. The team used human pluripotent ... cell in the body -- to grow the functional ... bacteria, a major cause of ulcers and stomach ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- Many ... near campus, even though tanning increases the risk ... popular among young adults, particularly white women, so ... students, health, the researchers said. "Public health ... student population awareness of the harms that indoor ...
(Date:10/30/2014)... News) -- A new vaccine that could help prevent ... by the U.S. Food and Drug Administration on Wednesday. ... ages of 10 and 25 from invasive meningococcal disease ... The bacteria can infect the bloodstream (sepsis) and ... It is a leading cause of bacterial meningitis, and ...
Breaking Medicine News(10 mins):Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:FDA Approves New Vaccine to Protect Against Meningitis 2
... In a survey of patients with chronic hepatitis C ... Digestive and Kidney Diseases-sponsored long-term treatment trial for patients ... approximately 40% acknowledged to interviewers at the time of ... the recent past used herbal products for health purposes. ...
... (TSX: MDS; NYSE:,MDZ), a leading provider of products ... filed restated 2007 quarterly reports under US GAAP,as ... 2007,annual report and financial statements in US GAAP ... restated quarterly reports also correct an error related ...
... APFC ) today announced that it will release ... 7, 2008. John R.,Gibson, Chairman and Chief Executive Officer, ... financial results and outlook of the,Company., The teleconference ... p.m.,PST. To access the call please dial (973) 582-2852 ...
... The Chrysler Foundation and,Kenosha (Wis.) Engine Plant today ... new Aquatics Center., Chrysler,s donation will help build ... the YMCA. The center will have two pools: a ... YMCA will break,ground for the aquatic center later this ...
... Iowa An anti-virus drug attacks influenza A by changing ... the virus to infect healthy cells, according to a recently ... Mei Hong, Iowa States John D. Corbett Professor in Chemistry, ... the effects of the antiviral drug amantadine on influenza A. ...
... research,organization, announced today that it has acquired the business ... located at Ninewells,Hospital and Medical School, Dundee, Scotland. Ninewells ... purchase of DDS supplements,Chiltern,s Clinical Research Unit in Slough ... has completed more than 700 Phase I trials.,The unit ...
Cached Medicine News:Health News:Silymarin does not affect virus activity or ALT levels in 2Health News:Silymarin does not affect virus activity or ALT levels in 3Health News:American Pacific to Release Financial Results and Hold Fiscal 2008 First Quarter Investor Teleconference 2Health News:The Chrysler Foundation and Kenosha Engine Plant Donate $100,000 to New YMCA Aquatics Center 2Health News:Iowa State chemists track how drug changes, blocks flu virus 2Health News:Chiltern Announced Today That it has Acquired the Business of Drug Development Solutions (DDS) 2Health News:Chiltern Announced Today That it has Acquired the Business of Drug Development Solutions (DDS) 3
... manual hemostasis analyzer that is ideal ... PTs, aPTTs, thrombins, fibrinogens and factor ... testing, this analyzer is small in ... time and labor saving benefits. Operation ...
... STart benchtop coagulation analyzers feature ... clot detection. This method eliminates ... other optically dense samples or ... and preprogrammed assays with curve ...
... Description,The STA-R Evolution is a fully-automated, ... the total laboratory automation line. Clotting, ... simultaneously in random access mode. The ... offers high throughput and rapid processing ...
The ACL 9000 together with an extensive test menu and superior technology is backed by high-quality service to keep the lab running efficiently....
Medicine Products: